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Background: Breast cancer is a complex multifactorial genetic disease. Among other factors, race and, to an even
greater extent, viruses are known to influence the development of this heterogeneous disease. It has been reported
that MMTV-like (HMTV) gene sequences with a 90 to 98% homology to mouse mammary tumor virus are found in
several populations with a prevalence range of 0 to 74%. In the Mexican population, 4.2% of patients with breast
cancer exhibit the presence of HMTV (MMTV-like) sequences. The aim of this study was to evaluate the presence
and current prevalence of retroviral HMTV (MMTV-like) sequences in breast cancer in Mexican women.
Methods: We used nested PCR and real-time PCR with a TaqMan probe. As a positive control, we used the C3H
MMTV strain inserted into pBR322 plasmid. To confirm that we had identified the HMTV sequences, we sequenced
the amplicons and compared these sequences with those of MMTV and HMTV (GenBank AF033807 and AF346816).
Results: A total of 12.4% of breast tumors were HMTV-positive, and 15.7% of the unaffected tissue samples from
458 patients were HMTV-positive. A total of 8.3% of the patients had both HMTV-positive tumor and adjacent
tissues. The HMTV-positive samples presented 98% similarity to the reported HMTV sequence.
Conclusions: These results confirm that the HMTV sequence is present in breast tumors and non-affected tissues in
the Mexican population. HMTV should be considered a prominent causative agent of breast cancer.
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Breast cancer (BC) is one of the most prevalent malig-
nancies in women worldwide, but the etiology of this
disease remains unclear and continues to be a health
problem as the leading cause of cancer death among
women [1-3]. Many studies indicate that this disease is
complex and multifactorial, and there are many risk
factors that promote tumor development, such as age,
parity, hormonal influence, diet, environment, geographic
location, a race and inherited genetic predisposition [4-6].
However, the molecular mechanisms related to breast* Correspondence: normandgarcia@gmail.com
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article, unless otherwise stated.carcinogenesis remain poorly understood, particularly
because of the biological heterogeneity of the disease [3].
BC is a multistep disease, and viral infection may play
a role in one or more of the steps in its pathogenesis
[7-11]. This hypothesis is based on the proven role of
mouse mammary tumor virus (MMTV) as the causal
agent of mammary tumors in mice [12-14]. Subsequently,
various investigators have shown that direct infection with
MMTV can infect human cells [9,15-18].
Some studies have indicated that a virus similar to
MMTV, namely MMTV-like virus, which is also known
as human mammary tumor virus (HMTV), may be a
risk factor for human BC [10,11].
Several studies have demonstrated the presence of the
MMTV-like env gene sequence with prevalences in the
range of 0 to 74% of BC cases in several countries, in-
cluding prevalences of 0% in Japan [19], Austria [20] andentral Ltd. This is an Open Access article distributed under the terms of the
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China [22], 31% in Argentina [17], 38% in Italy [17], 40%
in United States [23], 42% in Australia [11], and 74% in
Tunisia [17]. Mexico has reported a prevalence of 4.2%
[24]; thus, these data remain controversial. However,
other researchers have not been able to reproduce the
same results, which is attributed to the use of a different
methodology to identify the virus [25].
Pogo et al. [10] reported that inflammatory breast
cancer in American women shows a higher incidence
of viral sequences (71%) than sporadic breast cancers.
A similar incidence was found in inflammatory breast
cancers from Tunisia and in gestational breast cancers.
Because these conditions represent highly invasive malig-
nancies, it has been concluded that HMTV is sometimes
associated with a particularly malignant phenotype [10].
The presence of a human mammary tumor virus
(HMTV) has been reported with sequences [26] that are
90% to 98% homologous to MMTV, the etiological agent
of mammary tumors in mice [15,27]. It has been shown
that the retrovirus is found in greater frequency in
mammary tumors, and it is capable of integrating and
becoming expressed in mammary tissue. The presence
of MMTV or HMTV sequences has been investigated,
but these sequences are not always found in normal
breast tissue [11,18,24,26,28,29]. For example, HMTV
sequences have been found in 40% of breast cancers in
both American and Australian women, whereas viral
sequences were detected only in 1% of the non-affected
mammary tissues from the same patients [11].
The association of an HMTV agent with human breast
cancer remains controversial. The aim of this work was
to evaluate the presence and current prevalence of the
retrovirus HMTV (MMTV-like) sequences in BC in
Mexican women.
Methods
Patients and tissue samples
Breast tissue samples from 458 Mexican women were
collected between 2010 and 2013 at the Oncology
Services of the Oncology Hospital, National Medical
Center S-XXI, IMSS; Gynecology and Obstetrics Hospital
No. 3. National Medical Center “La Raza”, IMSS; Oncol-
ogy and Gynecology Hospital No. 4 Luis Castelazo Ayala,
IMSS; and the National Cancer Institute, SSA, Mexico
City Mexico. The histopathological diagnosis of each
tumor was performed according to the World Health
Organization criteria [30]. Samples were collected in sepa-
rated containers with dissection material (hypochlorite
5%, and sodium hydroxide 5 N for 1 hour) prepared for
each one and type of tissue (Tumor or normal breast
tissue), and for each procedure: pathology, surgery or
transport, to avoid any possible contamination from
viral DNA or cells.Cases were selected and matched with adjacent normal
breast tissue (at least 2 cm and far from the tumor lesion)
obtained at the time of the primary surgery. The sample
was frozen in liquid nitrogen and stored at −80°C until
use. Specimens were selected for analysis based on two
criteria: (i) the presence of sufficient material for analysis
and (ii) histological evaluation by two pathologists that
demonstrates that the samples contained at least 30%
tumor cells (in the case of the cancer samples). Represen-
tative sections from each case were paraffin-embedded for
staining with hematoxylin and eosin to assess the histopath-
ology diagnosis using the American Cancer Committee
criteria.
The design was a cross-sectional prospective study.
The study was approved by the Ethical Committee from
the National Scientific Research Commission of the IMSS
under the registration number 2008-785-067. Support
data are available through the LabArchives repository with
Accession Number DOI 10.6070/H47H1GHP. All of the
data were maintained under strict confidentiality and
complied with the National and International Regulations
for health research in humans. All of the experiments
were conducted in accordance with the Declaration of
Helsinki, and all of the subjects exhibited an adequate un-
derstanding of and provided written consent for all of the
procedures.
DNA extraction
The genomic DNA from frozen tumor and corresponding
normal breast tissues was extracted using TissueLyser
(Qiagen) for 20 seconds. The total DNA of each sample
was obtained from 10–50 mg of tissue using a DNeasy
Blood and Tissue Kit (Qiagen) with an automated QIAcube
(Qiagen) according to the manufacturer’s instructions. The
quantity and quality of the DNA determined through spec-
trophotometry by measuring the 260/280 ratio (NanoDrop,
Thermo Scientific). We increased the amount of starting
DNA from the samples that yielded low amounts of DNA
using a WGA1 kit (Sigma-Aldrich) following the manufac-
turer's instructions. The DNA was purified with a GenElute
PCR Clean-Up Kit (Sigma-Aldrich) and frozen at −80°C
until use. The DNA integrity was evaluated by amplifying a
700-bp sequence of the GAPDH gene (GenBank, Gene ID
2597, glyceraldehyde 3-phosphate dehydrogenase) [31]
followed by agarose electrophoresis. All of the PCR re-
agents were obtained from Life Technologies Invitrogen.
Detection of HMTV (MMTV-like) sequence by PCR
The detection of HMTV env gene-like sequences was
performed via nested PCR using the methods described
by Wang et al. [32]. Specifically, a 660-bp fragment was
amplified from the env gene of HMTV (MMTV-like)
using primers 1 (5'-CCTCACTGCCAGATC-3') and 4
(5'-GAATCGCTTGGCTCG-3') with 200 ng of DNA as
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primers 2 N (5'-TACATCTGCCTGTGTTAC-3') and 3 N
(5'-ATCTGTGGCATACCT-3’), resulting in a 250-bp PCR
product. The PCR products were analyzed by electrophor-
esis on 2.0% agarose gels stained with SyberGold 50X. As
a negative control, nuclease-free sterile water was reacted
with the primers in the absence of a template. The
pBR322 vector (Cat 45006, ATCC) containing the MMTV
env gene from the C3H strain (GenBank AF228552) and
propagated in Escherichia coli XL1 Blue [33] was used as
the positive control. All of the procedures were carried
out in a laminar flow hood exclusively used for PCR reac-
tions with human DNA.
Tests for mouse DNA and plasmid contamination
The Intracisternal A-type particle (IAP) PCR detection
to discard mouse DNA contamination was performed
with primers forward (5'- ATAATCTGCGCATGAGC
CAAGG-3') and reverse (5'- AGGAAGAACACCACA
GACCAGA-3’), resulting in product of variable size
between 200 and 300-bp, reflecting the diversity of the
IAP. The PCR products were analyzed by electrophoresis
on 2.0% agarose gels stained with GelRed 10X. As a
negative control, nuclease-free sterile water was reacted
with the primers in the absence of a template. Mouse
DNA was used as the positive control. Using the
methods described by Oakes et al. [34].
The PCR detection to discard plasmid contamination
was performed with primers TetCF (5'- AACAATGCGC
TCATCGT-3') and TetCR (5'- GGAGGCAGACAAG
GTAT-3’), resulting in a 1138-bp PCR product. The PCR
products were analyzed by electrophoresis on 2.0% agar-
ose gels stained with GelRed 10X. As a negative control,
nuclease-free sterile water was reacted with the primers in
the absence of a template. The pBR322 vector (Cat 45006,
ATCC) containing the MMTV env gene from the C3H
strain (GenBank AF228552) and propagated in Escheri-
chia coli XL1 Blue [33] was used as the positive control.
Using the methods described by Lucarelli et al. [35].
Support data are available through the LabArchives re-
pository with Accession Number DOI 10.6070/H4GH9FVX
Real-time PCR
To identify the samples positive for the HMTV (MMTV-
like) env gene, we designed primers and a TaqMan probe
based on the reported sequences of the full C3H MMTV
and human genomes (GenBank AF033807 and AF346816,
respectively) as follows: forward 5'-AAGGGTGATAAA
AGGCGTATGTG-3', location 5943–5964; reverse 5'- TT
TTGTATTGGCCCCTGAGTTC, location 5990–6011 -3';
and probe 5'-FAM-AACTTTGGTTGACTACCTT-MGB-
3', location 5969–5986. The reaction contained 100 ng of
DNA, 900 nM of each primer, 250 nM probe, and the
TaqMan Universal Master Mix II (Applied Biosystems).The reaction was performed according to the manufac-
turer’s instructions in a StepOne device (Applied Biosys-
tems) with 60 cycles (95°C for 15 min and 60°C for
60 min). As a negative control, nuclease-free sterile water
was reacted with the primers in the absence of a template,
and the MMTV env gene from the C3H strain (GenBank
AF228552) was used as a positive control. To calculate the
sensitivity of the test and the viral copy number, we gener-
ated a complete standard curve with the plasmid DNA
from the MMTV C3H strain by preparing serial dilutions
(10−1 – 10−7) for the positive control reaction with 1 ng of
template. All of the reactions were performed in duplicate.DNA sequencing
To confirm the presence of viral DNA and to rule out
the amplification of non-specific or endogenous retro-
viral sequences, the PCR products of selected positive
BC samples were sequenced. For this process, the
nested PCR products (250 bp) were removed from the
gel, purified using a Wizard SV gel and PCR Clean-up
system (A9282 Promega Corp., Madison. USA), and
submitted for sequencing to the Sequencing Unit facil-
ities at the Molecular Biochemistry Department, UBI-
PRO, FES-Iztacala, UNAM. All PCR products were
sequenced with an automatic capillary sequencer using
the Sanger method with fluorescent terminators (ABI
3100). Support data are available through the LabArc-
hives repository with the following accession numbers
for the unaffected and tumor sequences: DOI 10.6070/
H4MS3QQ6 and DOI 10.6070/H4C8277D, respectively.
The sequences were compared with GenBank (AF033807,
AF228552 and AF346816). The identity with HMTV
and MMTV was determined using GeneFisher 2. We
compared the sequencing data using the CLC Genomics
Workbench 7.0.4 analysis software. We aligned all of
the sequences using CLC Genomic Workbench software
with the following parameters: gap open cost, 10; gap
extension cost, 1; and alignment type, very accurate.
After alignment, we constructed a tree using the Neigh-
bor Joining Method with the Jukes-Cantor nucleotide
distance measure and performed bootstrap analysis with
100 replicates.Statistical analysis
Descriptive statistics were used for the analysis of each
of the study variables. The association between the
presence of MMTV-like sequences in tumors and
some sociodemographic and clinic data (age and type
of tumor) was determined. The X2 test was appropri-
ate for these analyses. P values of less than 0.05 were
considered statistically significant. All of the analyses
were performed using the SPSS 20 statistical software
package.
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Breast tissue samples
The presence of HMTV (MMTV-like) sequences in
tumor tissues and corresponding normal breast tissues
collected from 458 Mexican women with breast cancer
was determined. The tumor tissues were obtained from
patients with a mean age of 56 years (range 25–89 years),
and all of the samples were of sporadic tumors that had
not been treated. Of the 458 patients, 13 patients (2.84%)
had ductal carcinoma in situ, 301 patients (65.72%) had
infiltrating ductal carcinoma, 58 patients (12.66%) had
lobular carcinoma, 30 patients (6.55%) had mixed car-
cinoma (ductal-lobular), 12 patients (2.62%) had breast
fibroadenoma, 27 patients (5.9%) had some other type
of tumor, and there was no information provided for 17
patients (3.71%).
HMTV detection by nested PCR
The integrity of all of the DNA samples was validated by
PCR amplification of a 600-bp fragment of the GAPDH
gene. We detected HMTV (MMTV-like) through PCR
amplification of the env gene (Figure 1). Figure 1-A pre-
sents the 660-bp fragment corresponding to the positive
samples and controls obtained from the first PCR, and
Figure 1-B shows the fragment corresponding to the
250-bp band in the positive samples and controls, which
confirmed the presence of the amplified env gene frag-
ment. Figure 1-C shows the three patients in whom the
presence of HMTV was detected. Through the nested
PCR analysis, HMTV sequences were detected in 129
samples (14.08%) of the 916 DNA samples from tumor
and adjacent tissues. The prevalence of HMTV in the
tumor tissues was 12.4%, and that in the non-affected
breast tissues was 15.7%. In addition, the prevalence of
HMTV in both the tumor and adjacent tissues from the
same patient was 8.3%. An increased frequency of the
virus was observed in patients aged 46–55 years. There
was no significant difference between the tumor and adja-
cent tissue groups. The most frequent histopathologicalFigure 1 End-point PCRs for detection of the MMTV env gene in the s
gene fragment, exemplifying the expected results defining positive detecti
exemplifying the expected results defining positive detection. C. Three sam
product. MW: 100-bp molecular weight ladder; Neg: non-template negative
plasmid, used as a positive control; T: tumor; and NB: unaffected tissue.type was infiltrating ductal carcinoma (Table 1). Also all
positive samples were checked to discard plasmid and
mouse DNA contamination, accordingly to methods (data
not Show).
Verification of real-time PCR-positive samples
We performed real-time PCR with TaqMan probes cor-
responding to a different region of the env gene than the
region that was used for the nested PCR; however, we
used the same source of DNA, a 68-bp fragment located
from 5943 to 6011 (AF033807). Figure 2 shows the amp-
lification curves, which demonstrate that most of the
positive samples (96/129 positive samples; 74.41%), as
well as the negative and positive control, could be veri-
fied by this method. Of the 129 positive samples de-
tected by nested PCR, 33 (25.58%) could not be verified
with the TaqMan probes.
Sequence alignment and tree construction
To determine and verify the identity of the positive
samples, 96 samples (breast tumors and adjacent tissues)
were randomly selected. The PCR fragments were isolated
from the agarose gels and purified, and the DNA was
sequenced. Figure 3A shows the sequences of amplified
fragments. The sequences were aligned to the correspond-
ing region of the reported MMTV and HMTV sequences.
The comparison of MMTV with the consensus sequence
revealed a percentage of similarity of 99%. We also found
at least three bases in all sequenced samples that were
different from those in the reported MMTV sequence.
The comparison of HMTV with the consensus sequence
resulted in a percentage of similarity equal to 98%. As
shown in Figure 3B, at least six bases are different from
those in the reported HMTV sequence, and these bases
are present in all of the sequenced samples. The individual
sequence difference presented up to 88.8% homology with
the reported sequences.
We then performed a simultaneous alignment using
the 96 sequenced samples, MMTV, HMTV, and C3Hamples. A. First nested PCR round resulting in a 660-bp MMTV env
on. B. Second nested PCR round resulting in a 250-bp fragment,
ples that exemplify positive and negative detection of the 250-bp PCR
control; C3H: strain with MMTV env gene inserted into pBR322
Table 1 Prevalence of HMTV by sex, age and type of tumor
Prevalence % Tumor and normal breast tissues Tumor Normal breast tissues P value
Variables (n = 38/458) (n = 57/458) (n = 72/458)
8.3 12.4 15.7
Age (years)
25-35 1(2.6%) 3(5.3%) 1(1.4%) 0.129
36-45 7(8.4%) 12(21.1%) 12(16.7%)
46-55 15(39.5%) 21(36.8%) 21(29.2%)
56-65 11(28.9%) 13(22.8%) 29(40.3%)
66-75 4(10.5%) 6(10.5%) 8(11.1%9
76+ 0 2(3.5%) 1(1.4%)
P value 0.129
Histopathological type
Ductal carcinoma in situ 1(2.6%) 1(1.8%) 1(1.4%) 0.271
Infiltrating ductal carcinoma 28(73.7%) 41(71.9%) 56(77.8%)
Lobular carcinoma 6(15.8%) 9(15.8%) 12(16.7%)
Mixed carcinoma (ductal + lobular) 1(2.6%) 1(1.8%) 1(1.4%)
Breast fibroadenoma 0 0 0
No sufficient data 0 1(1.8%) 0
Others 2(5.3%) 4(7.0%) 2(8.3%)
P value 0.356
P < 0.001 was considered significant.
The cancer type classification was based on international criteria.
Cedro-Tanda et al. BMC Cancer 2014, 14:942 Page 5 of 9
http://www.biomedcentral.com/1471-2407/14/942strain to obtain a tree using the neighbor-joining method,
which is shown in Figure 3C. The tree forms three main
branches and shows the relationship between the samples
and the reported sequences for MMTV, HMTV and C3H.
We noted that the samples from the same patients (tumor
and unaffected tissues) remained near or not too far from
their corresponding matched samples, as exemplified by
the patient sample pairs 3A and 3 T, 9A and 9 T, 11A andFigure 2 Real-time PCR. The plot shows the amplification obtained using
nested PCR that yielded positive results. The probes are based in a differen
line represents a sample, positive control, or negative control. The PCR cyc
fluorescent units) are shown on the y-axis. All of the assays were performe11 T, 22-A and 22 T, and 73A and 73 T, and that MMTV
and HMTV tended to be in different groups or in different
branches.
Discussion
Since Bittner described the mouse mammary tumor virus
(MMTV) as the agent involved in mouse mammary
carcinogenesis in 1936, MMTV has been regarded as aTaqMan probes with the same DNA sources as those used for the
t region of the env gene, namely from 5943 to 6011 (AF033807). Each
les are shown on the x-axis, and the ΔRn values (representing the
d in 48-well plates.
Figure 3 Alignment and tree. A. Alignment of 96 samples against the MMTV sequence (AF033807). B. Alignment of 96 sample sequences
against the HMTV sequence (AF346816). C. Tree constructed by the neighbor-joining method. The tree contains 96 positive samples and depicts
the relationship among them, MMTV, HMTV and C3H.
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absence of MMTV-like virus in breast cancer samples
from several populations has been reported in the last
five decades. The presence of the virus has been measured
by sequencing and immunoreactivity against the envelope
protein (Env), and retroviral particles have even been
found in normal human milk samples [10].
The current technology and the developed methodolo-
gies allow us to distinguish exogenous sequences that
are not present in the human genome that are 95% to
99% homologous to MMTV [32]. A low prevalence or
absence of the viral sequences has been reported in
normal tissue, ruling out the germline transmission of or
polymorphisms in endogenous retroviral sequences [28].
Since the beginning of this century, this retrovirus has
been designated a human mammary tumor virus (HMTV)
[27]. In this study, we found an HMTV prevalence of
12.4% in breast cancer samples, with a higher prevalence
among women aged 46–55 years, which is similar to the
prevalence reported in other studies. In the Mexicanpopulation (northeastern Mestizo), the prevalence of
MMTV-like sequences in breast cancer patients has been
reported to be 4.2% (n = 119) [24]. We decided to increase
the size of the population (n = 458) and to determine the
presence of HMTV in breast cancer vs. normal breast tis-
sues within the same patient. Surprisingly, we observed a
15.7% prevalence of HMTV in normal breast tissue, with
a higher prevalence among women aged 56–65 years. This
prevalence was higher than that found in previous studies.
The presence of the retrovirus in breast tumor and normal
breast tissue samples from an individual patient presented
a prevalence of 8.3%. We confirmed and extended previ-
ous findings showing that the differences in the prevalence
of HMTV (MMTV-like) gene sequences and breast cancer
rates among populations may be related to the geographic
distribution [22].
We agree with the model that HMTV is not passed
down through the germ line because it would then be
present in all cells of a given patient, although this possi-
bility remains a latent question regarding transmission
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ing the increased presence of HMTV in normal breast
tissue. We can dismiss the possibility of contamination
because we strictly followed the appropriate technical
methods, such as working in a fume hood exclusively
used for human DNA. In addition, our staff never
worked with murine lines or genetic material, and the
positive controls were prepared separately. It has been
proven by this method that the env gene is not present
in humans and is different than HERVs (human en-
dogenous retroviruses) [10]. We checked all samples to
discard contamination to avoid false positives from
mouse DNA or plasmid, corroborating the correct samples
management. Supporting our present results, in which nor-
mal cells even far from the tumor or near, are infected but
they are not yet transformed.
Therefore, we verified the HMTV positivity using two
distinct methods. We designed new primers and a TaqMan
probe for a different region 36 bp from the fragment amp-
lified by the nested method. These primers were based on
the same reported sequence, and we expected to corrob-
orate all of the positive results obtained by nested PCR.
However, we could only verify the results found for
74.41% (96/129) of the samples that were found to be
positive by nested PCR, as well the controls, and randomly
selected patient samples that had been found to be nega-
tive by nested PCR patient samples. We assume that this
difference is due to the fact that was because the retro-
virus has a high rate of mutation, with a reported hom-
ology of 90% to 98% [9,10,23]. In addition, it is known
that the TaqMan systems are specific and sensitive, and
they do not accept base changes.
To determine the identity of the amplified samples, we
sequenced the 250-bp fragment from 96 positive sam-
ples by the Sanger method. The sequences were aligned
and compared with the reported references for MMTV
and HMTV. Because the sequences are not very long, it
is difficult to establish the presence of the complete virus
and to determine whether the sequence varies even
within the same patient. However, with the generated
data, we could appreciate that, even though the Env
gene is a conserved sequence, we did find polymorphism
among the samples with up to 88.8% homology. This
finding also corroborates the lack of contamination and
also highlights differences between the reported sequences
for MMTV and HMTV and the consensus sequence,
which revealed three to six different bases. Our results
also support the contention that these sequences may rep-
resent a virus associated with human breast carcinogenesis
[22]. The analysis suggests that there are two different vi-
ruses. The similarity between the sequences indicates that
they are closely related but not identical.
The presence of HMTV gene sequences may contrib-
ute to the development or progression of carcinogenesis.Thirty-eight of the evaluated patients had both tumor
and unaffected tissues that presented positive results, and
we observed similarity among the amplified sequences in
the constructed tree due to the fact that they were posi-
tioned in the same branch and had similar homology to
one another. This observation may indicate two independ-
ent infections or an infection of common origin with or
without a mutation in HMTV. The mechanism through
which MMTV may contribute to breast cancer in mice is
known: the virus reaches the cell, the RNA is converted to
DNA, and the DNA is integrated into the host genome in
certain specific locations. It has also been shown that the
envelope gene of MMTV alone can cause murine cells
and human mammary cells to become cancerous, and the
overexpression of the envelope gene may be the cause of
certain cancers [8]. The capsid is one of the proteins on
the outside of the virus particle, and it is believed that this
protein connects the virus to the host cell receptor and
likely helps it penetrate into cells. It is known that the en-
velope contains ITAM (immunoreceptor activation motif
based on tyrosine), which stimulates certain hormones
and is suggested to contribute to the initiation of breast
cancer. Env and ITAM proteins in human breast cancer
are likely oncoproteins [36]. The proviral structure is
replication-competent, and its long terminal repeat [3]
contains several hormone-responsive elements and the
open reading frame for superantigen [10,37]. Regarding
HMTV and human non-affected mammary cells, there is
strong evidence of the presence of HMTV in human
breast cancer, but the receptor that is used to penetrate
into the cell is not know, and mechanism that allows the
virus to infect the host is not clearly understood. In
addition, we hypothesize that the virus effect may depend
on the site of insertion of the retrovirus. In 2007, Theo-
dorou et al. performed a high-throughput retroviral inser-
tional mutagenesis screen in mouse mammary tumor
virus (MMTV)-induced mammary tumors and identified
33 common insertion sites, of which 17 were previously
not known to be associated with mammary cancer and 13
had not been previously linked to cancer in general [38].
Consequently, there should be differences among breast
cancer samples and unaffected tissues related to the pres-
ence of HMTV and the sites of insertion. If the retrovirus
gets inserted into a region that activates an oncogene or
inactivates a tumor suppressor or repair gene, the inser-
tion may alter signaling pathways and contribute to tumor
development or progression by insertional mutagenesis. In
addition, insertion may simply trigger the neoplastic
process that is waiting to start. In contrast, if the retro-
virus inserts into a site with no significant biological func-
tion (due to the large amount of LTRs along the human
genome), the cell will not be damaged, and the presence
of viral DNA will simply become a risk factor, as in the
case of infected normal tissue. We would like to reinforce
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considered a HERV. Moreover, the insertional mutagen-
esis caused by HMTV may explain the heterogeneity
found in breast cancer tumors. This heterogeneity limits
an accurate response to treatment because the infection
may occur before or after neoplastic transformation. Ac-
cording to the present data, it is necessary to look deeper
for the mechanism of infection of this retrovirus in
humans, to determine the contribution of HMTV to the
development and progression of breast cancer (or any
neoplasia), to identify the sites of insertion and define the
mutagenesis that insertion may cause, to detect the
presence of the virus in serum for diagnostic purposes,
to prevent the infection by identifying and therapeutic-
ally blocking the receptor, and to correlate infection
with tumor aggressiveness when infection is present.
We are currently subjecting the positive samples to
NGS (next-generation sequencing) in order to identify
the insertion sites in our samples, which would allow us
to discard HERVs from new insertions. We hypothesize
that this strategy will help us investigate whether the
presence of HMTV in women and in the mammary
gland is a risk factor for oncogenesis. We also hypothesize
that this strategy will contribute to the determination of
whether HMTV provokes viral oncogenesis and whether
it is indeed a prominent causative agent of breast cancer.
As was shown recently, the importance of identifying the
heterogeneity at the molecular and genomic levels will
provide important data for studying specific types of
human breast cancer [39]. Understanding retroviral
behavior will contribute to the development of immuno-
logical therapies against cancer, and further research will
aid the diagnosis, treatment and prevention of cancer
caused by viruses [40].Conclusions
These results confirm that the HMTV sequence is present
in the Mexican population, in both breast tumors and un-
affected tissue. There is strong evidence supporting the
presence of HMTV in human breast cancer, which rein-
forces the conclusion that viruses in humans are acquired
and should be considered if HMTV is indeed a prominent
causative agent of breast cancer. Insertional mutagenesis
caused by HMTV may explain the heterogeneity found in
breast cancer tumors and its innocuous presence in un-
affected mammary gland tissue in women.
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